[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Artiva Biotherapeutics Inc (ARTV)

Artiva Biotherapeutics Inc (ARTV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 263,977
  • Shares Outstanding, K 24,717
  • Annual Sales, $ 0 K
  • Annual Income, $ -83,870 K
  • EBIT $ -68 M
  • EBITDA $ -87 M
  • 60-Month Beta 2.86
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.95

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.74
  • Number of Estimates 3
  • High Estimate $-0.48
  • Low Estimate $-0.95
  • Prior Year $-0.87
  • Growth Rate Est. (year over year) +14.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.52 +20.95%
on 04/29/26
14.53 -29.08%
on 04/20/26
+1.20 (+13.24%)
since 04/15/26
3-Month
3.87 +166.28%
on 02/17/26
14.53 -29.08%
on 04/20/26
+6.31 (+157.63%)
since 02/13/26
52-Week
1.47 +601.02%
on 06/27/25
14.53 -29.08%
on 04/20/26
+8.18 (+383.80%)
since 05/15/25

Most Recent Stories

More News
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase

EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:ARTV),(NASDAQ:FATE),(NASDAQ:IBRX),(NASDAQ:CHRS) EQNX::TICKER_END

CHRS : 1.5750 (-3.37%)
GTBP : 0.4001 (-8.84%)
FATE : 1.7600 (-7.37%)
ARTV : 9.96 (-6.74%)
IBRX : 8.05 (-1.23%)
Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell...

ARTV : 9.96 (-6.74%)
Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

Initial AlloNK® (AB-101) clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in the company-sponsored Phase 2a basket trial,...

ARTV : 9.96 (-6.74%)
Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026

Initial clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in the company-sponsored Phase 2a basket trial, with no patients...

ARTV : 9.96 (-6.74%)
2 Small-Cap Stocks With Big Potential to Buy Under $30

These under-$30 stocks are betting on innovative therapies that could unlock massive long-term value.

JBIO : 22.63 (-6.22%)
ARTV : 9.96 (-6.74%)
Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

SAN DIEGO, April 08, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies...

ARTV : 9.96 (-6.74%)
Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights

Initial clinical response data for AlloNK ® in refractory rheumatoid arthritis (RA) expected in first half of 2026 U.S. Food and Drug Administration (FDA) interaction to discuss potential pivotal...

ARTV : 9.96 (-6.74%)
Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies...

ARTV : 9.96 (-6.74%)
Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant

SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible...

ARTV : 9.96 (-6.74%)
Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors

SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible...

ARTV : 9.96 (-6.74%)

Business Summary

Artiva Biotherapeutics Inc. is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. The company's lead program includes AlloNK(R). Artiva Biotherapeutics Inc. is based in SAN DIEGO....

See More

Key Turning Points

3rd Resistance Point 12.62
2nd Resistance Point 12.06
1st Resistance Point 11.37
Last Price 9.96
1st Support Level 10.12
2nd Support Level 9.56
3rd Support Level 8.87

See More

52-Week High 14.53
Last Price 9.96
Fibonacci 61.8% 9.54
Fibonacci 50% 8.00
Fibonacci 38.2% 6.46
52-Week Low 1.47

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.